医学
多塔
乳腺癌
癌症
放射科
核医学
肿瘤科
内科学
有机化学
化学
螯合作用
作者
Jia Deng,Jian Yang,Zixuan Cheng,Yue Chen
出处
期刊:Clinical Nuclear Medicine
[Ovid Technologies (Wolters Kluwer)]
日期:2024-03-25
卷期号:49 (7): 659-661
标识
DOI:10.1097/rlu.0000000000005193
摘要
Bone metastasis of breast cancer often presents as osteolytic. 177 Lu-DOTA-ibandronic acid ( 177 Lu-DOTA-IBA) is a new radioactive drug for bone metastasis lesion. We report a case of recurrent intermittent pain due to bone metastasis, who demonstrated a satisfactory therapy response after 2 cycles of 177 Lu-DOTA-IBA. In addition, the patient did not have any observable adverse effects.
科研通智能强力驱动
Strongly Powered by AbleSci AI